Stoke Therapeutics, Inc.
NASDAQ: STOK. Canonical company identity and public leadership record.
US
- Alpha ID
- alpha:company:bbe1f85f-8f37-4051-a3de-418dac6ca3ee
- SEC CIK
- 0001623526
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 17, 2026
- Newest evidence
- Apr 22, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Ian F. SmithChief Executive Officer
- Chair
- Arthur O. Tzianabos, Ph.D.
- Independent
- Not published6 directors published
- Published claims
- 242 distinct sources
- Evidence records
- 50 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 5 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
EXECUTIVE APPOINTED
Barry S. Ticho executive of Stoke Therapeutics, Inc., effective 2026-04-22.
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Chief Medical Officer | Barry S. Ticho | Apr 2026 | current | Source reportedE4 |
| General Counsel and Corporate Secretary | Jonathan Allan | Apr 2026 | current | Source reportedE5 |
| Chief Medical Officer | Barry S. Ticho, M.D., Ph.D., FACC | Not captured | unknown | Source reportedE2 |
| Chief Executive Officer | Ian F. Smith | Not captured | unknown | Source reportedE2 |
| Chief Patient Officer | Jason Hoitt | Not captured | unknown | Source reportedE2 |
| General Counsel and Corporate Secretary | Jonathan Allan, J.D. | Not captured | unknown | Source reportedE2 |
| Chief Financial Officer | Thomas E. Leggett | Not captured | unknown | Source reportedE2 |
Board of directors
Evidence6 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Arthur A. Levin | Independence not published | 2015 | None published | Source reportedE3 |
| Arthur O. Tzianabos | Independence not published | 2024 | None published | Source reportedE3 |
| Edward M. Kaye | Independence not published | 2017 | None published | Source reportedE3 |
| G. Clare Kahn | Independence not published | 2026 | None published | Source reportedE3 |
| Jennifer C. Burstein | Independence not published | 2019 | None published | Source reportedE3 |
| Stoke Therapeutics | Independence not published | 2014 | None published | Source reportedE3 |
| Adrian R. Krainer, Ph.D. | Independent | Not published | None published | Source reportedE2 |
| Arthur O. Tzianabos, Ph.D. | IndependentChair | Not published | None published | Source reportedE2 |
| Edward M. Kaye, M.D. | Independent | Not published | None published | Source reportedE2 |
| G. Clare Kahn, Ph.D. | Independent | Not published | None published | Source reportedE2 |
| Ian F. Smith | Not independent | Not published | None published | Source reportedE2 |
| Julie Anne Smith | Independent | Not published | None published | Source reportedE2 |
| Seth L. Harrison, M.D. | Independent | Not published | None published | Source reportedE2 |
Committees and risk ownership
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Financials and market context
EvidenceGovernance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- CommitteesNot reviewed. Committee mandates show where oversight is delegated.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Barry S. TichoChief Medical Officercompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:18
- Jonathan AllanGeneral Counsel and Corporate Secretarycompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:22
- Barry S. Ticho, M.D., Ph.D., FACCChief Medical Officercompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:19
- Ian F. SmithChief Executive Officer; Chief Executive Officer and Directorcompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:20, company:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:13
- Jason HoittChief Patient Officercompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:21
- Jonathan Allan, J.D.General Counsel and Corporate Secretarycompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:23
- Thomas E. LeggettChief Financial Officercompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:24
- Arthur A. LevinDirectorcompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:7
- Arthur O. TzianabosDirectorcompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:8
- Edward M. KayeDirectorcompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:9
- G. Clare KahnDirectorcompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:11
- Jennifer C. BursteinDirectorcompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:14
- Stoke TherapeuticsDirectorcompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:17
- Adrian R. Krainer, Ph.D.Directorcompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:6
- Arthur O. Tzianabos, Ph.D.Chairman of the Boardcompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:5
- Edward M. Kaye, M.D.Directorcompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:10
- G. Clare Kahn, Ph.D.Directorcompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:12
- Julie Anne SmithDirectorcompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:15
- Seth L. Harrison, M.D.Directorcompany:bbe1f85f-8f37-4051-a3de-418dac6ca3ee:leadership_role:16
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 5 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 17, 2026. Cited by 4 Claims.
- E2sec def 14a. Published Apr 22, 2026. Retrieved Sep 13, 2026. Cited by 12 Claims.
- E3sec proxy. Published Apr 22, 2026. Retrieved Sep 2, 2026. Cited by 6 Claims.
- E4sec filing. Published Apr 22, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E5sec filing. Published Apr 22, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 17, 2026- Barry S. Ticho executive of Stoke Therapeutics, Inc., effective 2026-04-22.
- Jonathan Allan executive of Stoke Therapeutics, Inc., effective 2026-04-22.
- G. Clare Kahn seat on Stoke Therapeutics, Inc., effective 2026-01-01.
- Arthur O. Tzianabos seat on Stoke Therapeutics, Inc., effective 2024-01-01.
- Jennifer C. Burstein seat on Stoke Therapeutics, Inc., effective 2019-01-01.
- Edward M. Kaye seat on Stoke Therapeutics, Inc., effective 2017-01-01.
- Arthur A. Levin seat on Stoke Therapeutics, Inc., effective 2015-01-01.
- Stoke Therapeutics seat on Stoke Therapeutics, Inc., effective 2014-01-01.

